Three-year outcomes in a randomized single-blind controlled trial of intravitreal ranibizumab and oral supplementation with docosahexaenoic Acid and antioxidants for diabetic macular edema
Ficheros
Compartir
Estadísticas
Ver Estadísticas de usoMetadatos
Mostrar el registro completo del ítemAutor/es
Lafuente, María; Ortín, Lourdes; Argente, María; Guindo, José L.; López Bernal, María D.; [et al.]Fecha
2019Disciplina/s
MedicinaResumen
Purpose: To report 3-year results of a randomized single-blind controlled trial of intravitreal ranibizumab combined with oral docosahexaenoic acid (DHA) supplementation versus ranibizumab alone in patients with diabetic macular edema.
Methods: There were 26 patients (31 eyes) in the DHA group and 29 (38 eyes) in the control group. Ranibizumab (0.5 mg) was administered monthly for the first 4 months followed by a pro re nata (PRN) regimen. In the experimental group, patients received oral DHA supplementation (1,050 mg/day) (Brudyretina 1.5 g).
Results: At 36 months, mean decrease of central subfield macular thickness was higher in the DHA-supplementation group than in controls (275 ± 50 mm vs. 310 ± 97 mm) with significant differences at Months 25, 30, 33, and 34. Between-group differences in bestcorrected visual acuity were not found, but the percentages of ETRDS gains .5 and .10 letters were higher in the DHA-supplementation group. Differences serum HbA1c, plasma total antioxid...